



## Sage Therapeutics to Present at Goldman Sachs 39th Annual Global Healthcare Conference

June 8, 2018

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun. 8, 2018-- Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that the Company will present at the Goldman Sachs 39<sup>th</sup> Annual Global Healthcare Conference on Tuesday, June 12, 2018 at 9:20 A.M. PT (12:20 P.M. ET) in Rancho Palos Verdes, CA.

A live webcast of the presentation can be accessed on the investor page of Sage's website at [investor.sagerx.com](http://investor.sagerx.com). A replay of the webcast will also be archived for up to 30 days on Sage's website following the conference.

### About Sage Therapeutics

Sage Therapeutics is a clinical-stage biopharmaceutical company committed to developing novel medicines to transform the lives of patients with life-altering CNS disorders. Sage has a portfolio of novel product candidates targeting critical CNS receptor systems, GABA<sub>A</sub> and NMDA. Sage's lead program, a proprietary IV formulation of brexanolone (SAGE-547), has completed Phase 3 clinical development for postpartum depression and a New Drug Application is currently under review with the U.S. Food and Drug Administration. Sage is developing its next generation modulators, including SAGE-217 and SAGE-718, in various CNS disorders. For more information, please visit [www.sagerx.com](http://www.sagerx.com).

View source version on businesswire.com: <https://www.businesswire.com/news/home/20180608005078/en/>

Source: Sage Therapeutics

### Sage Therapeutics

#### Investor:

Paul Cox, 617-299-8377

[paul.cox@sagerx.com](mailto:paul.cox@sagerx.com)

or

#### Media:

Maureen L. Suda, 585-355-1134

[maureen.suda@sagerx.com](mailto:maureen.suda@sagerx.com)